Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
03 December 2021 | Story Lunga Luthuli | Photo Supplied
Geraldine Lengau, Senior Officer in the UFS Gender Equality and Anti-Discrimination Office within the Unit for Institutional Change and Social Justice, calls on men to take the lead in ending gender-based violence.

Gender-based violence is a phenomenon deeply rooted in gender inequality and the scourge continues to be one of the most notable human rights violations, with many communities – especially women and children – suffering the most from the atrocious acts. 

South Africa remains the country with the highest number of violent acts, especially against women, and Statistics South Africa reports that one in five partnered women has experienced physical violence. 

Gender-based violence can take many forms, including 

• sexual harassment; 
• rape and/or sexual violence;
• stalking (deliberately and repeatedly following, watching, and/or harassing another person);
• physical, emotional, and economic abuse; and
• child abuse.

Geraldine Lengau, Senior Officer in the Gender Equality and Anti-Discrimination Office within the Unit for Institutional Change and Social Justice, says: “Individuals must be vigilant of toxic environments where emotional and physical abuse are rampant.”

 “Even in the workplace, individuals can experience gender-based violence and it can play itself out in the form of power dynamics, prejudice, and discrimination.”

To help end gender-based violence at work, Lengau says, “Institutions have a duty to implement policies and procedures to increase awareness and sensitisation about this pandemic.”

Societal norms often contribute to victims deciding not to report these criminal acts for fear of being judged, with many women still being considered guilty of attracting violence against themselves through their behaviour.

“It is important for communities to provide support to victims and for organisations to have a zero gender-based violence tolerance policy. Victims must report any act, and in extreme cases, they must not be shy to get a protection order,” Lengau says. 

With the 16 Days of Activism for No Violence against Women and Children Campaign in full swing, Lengau says, “It is a great international initiative to tackle and raise awareness around issues of gender-based violence; however, it is not enough. It should go beyond the 16 days.”

 “To rid society of gender-based violence, our communities – men and women – should work together to root it out. Men should take the lead in tackling issues and bringing about solutions. Women should never get tired of speaking out; there is help for them.”

“Gender-based violence is a societal ill and women need to know that they should not bear the shame,” she says.

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept